Antiplatelet agents for chronic kidney disease (Q24200752)

9

0 references

Suetonia Palmer

1

0 references

Jonathan Craig

4

Jonathan C Craig

0 references

Giovanni Strippoli

10

Giovanni FM Strippoli

0 references

Angela Webster

8

Angela C Webster

0 references

Lucia Di Micco

2

Lucia Di Micco

0 references

Mona Razavian

3

Mona Razavian

0 references

Fabio Pellegrini

6

Fabio Pellegrini

0 references

Meg Jardine

7

Cochrane Database of Systematic Reviews

Meg J Jardine

0 references

publication date

28 February 2013

0 references

published in

0 references

cites work

Prevention of p.o. clotting of av. cimino fistulae with Acetylsalicyl acid results of a prospective double blind study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISM

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Renal function and outcomes in acute coronary syndrome: impact of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Effect of dipyridamole plus aspirin on hemodialysis graft patency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Prevention of Thrombosis in Patients on Hemodialysis by Low-Dose Aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Final report on the aspirin component of the ongoing Physicians' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Embolic protection and platelet inhibition during renal artery stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Complete versus partial distal embolic protection during renal artery stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Renal function, concomitant medication use and outcomes following acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Cardiovascular Mortality in End-Stage Renal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Cardiovascular and noncardiovascular mortality among patients starting dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Pathophysiology of cardiovascular disease and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

The burden of adult hypertension in the United States 1999 to 2000: a rising tide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Chronic renal failure: a cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Major bleeding in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Platelet dysfunction and end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Long-term survival in renal transplant recipients with graft function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Cardiac problems in the dialysis patient: beyond coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Bleeding in renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Medications in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Meta-analysis of antiplatelet therapy for IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Chronic kidney disease increases risk for venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Kidney disease as a risk factor for recurrent cardiovascular disease and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Antiplatelet agents for chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Membranoproliferative Glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

The effect of sulphinpyrazone and alpha-tocopherol on platelet activation and function in haemodialysed patients

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis--a multicenter collaborative double blind study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Reduction of thrombus formation on dialyser membranes by aspirin and RA 233

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Augmentation of peritoneal clearance by dipyridamole

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Clinical and echocardiographic disease in patients starting end-stage renal disease therapy

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

The Hypertension Optimal Treatment (HOT) study: results of 12-month therapy related to age

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Cardiovascular morbidity and risk factors in renal transplant patients

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients?

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS)

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Prevention of platelet deposition and thrombus formation on hemodialysis membranes: a double-blind randomized trial of aspirin and dipyridamole

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021

Meta-analysis: vitamin D compounds in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008834.PUB2

7 January 2021